Exploratory Trial to Assess Mechanism of Action, Clinical Effect, Safety and Tolerability of 12 Weeks of Treatment With BI 655130 in Patients With Active Ulcerative Colitis (UC)

Trial Profile

Exploratory Trial to Assess Mechanism of Action, Clinical Effect, Safety and Tolerability of 12 Weeks of Treatment With BI 655130 in Patients With Active Ulcerative Colitis (UC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2018

At a glance

  • Drugs BI 655130 (Primary)
  • Indications Ulcerative colitis
  • Focus Pharmacodynamics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 29 Jun 2018 This study has been changed from suspended to recruiting in Germany.
    • 31 May 2018 Planned End Date changed from 5 Mar 2019 to 14 Jun 2019.
    • 31 May 2018 Planned primary completion date changed from 13 Nov 2018 to 22 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top